Avenzo collects another $60M for two small molecules and two ADCs licensed from China

Avenzo Therapeutics, an early adopter of the China-to-US licensing model, has brought in another $60 million for its four investigational cancer treatments. With the Series B, the San Diego-based biotech has now raised $446 million ...